Singapore markets close in 2 hours 35 minutes
Straits Times Index
3,318.50 +10.60 (+0.32%) Nikkei
39,103.22 +486.12 (+1.26%) Hang Seng
18,859.31 -336.29 (-1.75%) FTSE 100
8,370.33 -46.12 (-0.55%) Bitcoin USD
69,396.29 -496.54 (-0.71%) CMC Crypto 200
1,510.94 +8.28 (+0.55%)
SciClone Pharmaceuticals (Holdings) Limited (6600.HK)
HKSE - HKSE Delayed price. Currency in HKD
Add to watchlist
As of 02:09PM HKT. Market open.
| Previous close | 18.320 |
| Open | 18.300 |
| Bid | 18.320 x N/A |
| Ask | 18.340 x N/A |
| Day's range | 18.300 - 18.360 |
| 52-week range | 8.750 - 18.480 |
| Volume | |
| Avg. volume | 4,453,114 |
| Market cap | 11.486B |
| Beta (5Y monthly) | 0.77 |
| PE ratio (TTM) | 9.90 |
| EPS (TTM) | 1.850 |
| Earnings date | 28 Mar 2024 |
| Forward dividend & yield | 0.39 (2.13%) |
| Ex-dividend date | 02 Jun 2023 |
| 1y target est | 18.24 |
Business WireMenarini Group and SciClone Pharmaceuticals Announce Exclusive Sub-Licensing Collaboration to Develop and Commercialize ORSERDU® (Elacestrant) in China to Address Advanced or Metastatic Breast Cancer
FLORENCE, Italy & HONG KONG, November 07, 2023--The Menarini Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and SciClone Pharmaceuticals (Holdings) Ltd. ("SciClone"), an international biopharmaceutical company, today announced that they have entered into an exclusive sub-licensing agreement to develop and commercialize ORSERDU® (elacestrant) in the People’s Republic of China (China), in an effort to expand treatment options for appropriate metastatic breast c
© 2024 Yahoo. All rights reserved.